Cryoport Provides Cryogenic Logistics Solutions to HemaCare Corporation
LAKE FOREST, Calif., July 30, 2015 /PRNewswire/ — Cryoport, Inc. (NASDAQ:CYRX) (“Cryoport” or the “Company”), the leading provider of advanced cryogenic logistics solutions for the life sciences industry, serving markets including immunotherapies, stem cells, cell lines, clinical research organizations, vaccine manufacturers, animal health, and reproductive medicine, today announced that the Company will provide cryogenic logistics solutions to HemaCare Corporation (“HemaCare”), a leading global provider of high-quality biological material to the scientific community.
Jerrell Shelton, CEO of Cryoport, commented, “We are pleased to be able to support HemaCare with their efforts to supply the research community with crucial blood products. The uniqueness of their product offerings requires a trusted provider. Cryoport has been gaining a strong reputation within the scientific community as well as the broader life sciences industry as the premier solutions provider for cryogenic logistics.”
Under terms of the agreement, Cryoport will provide cold chain logistics for a broad range of cell and tissue samples for use in advanced biomedical research, cell therapy clinical trials and product commercialization.
“Maintaining the quality and integrity of our products is an essential component to achieving favorable research outcomes, and something our customers have come to expect from us,” said Pete van der Wal, President and CEO of HemaCare. “Cryoport’s shared commitment to quality and reputation for the highest packaging and shipping standards ensures that our products are delivered without significant loss of viable, functional cells.”
Cryoport’s global network has the capacity to support the demand of research communities across the globe. Cryoport’s validated and comprehensive cryogenic logistics solutions will ensure that the integrity of the shipment is maintained throughout the entire process, which is critical to the validity of all research.
About Cryoport, Inc.
Cryoport is the premier provider of cryogenic logistics solutions to the life sciences industry through its purpose-built proprietary packaging, information technology and specialized cold chain logistics expertise. We provide leading edge logistics solutions for biologic materials such as immunotherapies, stem cells, CAR-T cells, and reproductive cells for clients worldwide including points-of-care, CRO’s, central laboratories, pharmaceutical companies, contract manufacturers, and university researchers. Our packaging is built around our proprietary Cryoport Express® liquid nitrogen dry vapor shippers, which are validated to maintain a constant -150°C temperature for a 10 day dynamic shipment duration. Our information technology centers around our Cryoportal™ Logistics Management Platform, which facilitates management of the entire shipment process. Cryoport is the preferred cryogenic logistics solutions partner to the world’s largest shipping companies controlling more than 85% of the world’s air shipments. For more information, visitwww.cryoport.com.
To download Cryoport’s investor relations app, which offers access to SEC documents, press releases, videos, audiocasts and more, please click to download from your iPhone and iPad or Android mobile device.
About HemaCare Corporation
Since 1978, HemaCare Bioresearch Products & Services has been the trusted research partner of choice from concept to commercialization. Built on a 37-year history in apheresis collection, HemaCare is a leader in Cell and Tissue Collection, Processing and Cell Therapy, providing the high-quality biological material needed to ensure quality research outcomes that meet the unique needs of the scientific community. For more information, please visit www.hemacare.com.
Forward Looking Statements
Statements in this news release which are not purely historical, including statements regarding Cryoport, Inc.’s intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. It is important to note that the company’s actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic conditions, trends in the products markets, variations in the company’s cash flow, market acceptance risks, and technical development risks. The company’s business could be affected by a number of other factors, including the risk factors listed from time to time in the company’s SEC reports including, but not limited to, the annual report on Form 10-K for the year ended March 31, 2015. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Cryoport, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.